Who We Are
Bolt Biotherapeutics, based in the San Francisco Bay Area, is a clinical-stage biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), a new class of immuno-oncology therapeutics. This is a unique opportunity to join and build, with like-minded colleagues, a company that will transform the lives of individuals with cancer.
At Bolt Biotherapeutics, we are seeking for highly motivated Research Associate to join our research bioconjugation team. The primary responsibility of the successful candidate is to perform variety of antibody conjugation chemistries and techniques to support discovery and pipeline programs.
Responsibilities:
- Perform conjugation (lysine, cysteine, site specific etc.) of antibodies to diverse linker-payloads on mg to gram scale, following established protocols and procedures.
- Conduct purification of the antibody drug conjugates utilizing various chromatographic techniques (affinity chromatography, size exclusion chromatography, ion exchange chromatography, membrane filtration (TFF) etc.)
- Perform analytical characterization of the antibodies and bioconjugates using analytical techniques including UV-Vis, HIC, SEC, RP-HPLC, and LC-MS.
- Maintain accurate records of experiments, results and analytical data. Adhere to safety guidelines and protocols in the laboratory environment.
Qualifications:
- Bachelor's or Master's degree in biochemistry or related discipline with 2+ years of industrial or academic experience in bioconjugation.
- Hands on experience with conjugation, purification and analytical characterization of antibody drug conjugates.
- Ability to work both independently & collaboratively and willingness to learn new bioconjugation chemistries/techniques.
- Strong communication skills, collaborative, self-motivated, goal-oriented and strong teamwork in a fast-paced setting.
We are an Equal Opportunity Employer offering a competitive salary and benefits package. Applicants should be legally entitled to work for any employer in the US.
Bolt Biotherapeutics requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment. As required by applicable law, Bolt will consider requests for Reasonable Accommodations.
Note to Employment Agencies: Please do not forward any agency resumes. The company will not be responsible for any fees related to resumes that are unsolicited.
What We Do
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.